FDA OKs Neuron Therapeutics' lumbar catheter:
This article was originally published in Clinica
The US FDA has cleared for sale Neuron Therapeutics' lumbar catheter for draining cerebrospinal fluid (CSF) from the space surrounding the spinal cord. Compared with existing lumbar drainage products, the new catheter can transport CSF at significantly higher flow rates, is less likely to collapse or become obstructed and has improved handling characteristics, claims the Malvern, Pennsylvania firm. The catheter is part of Neuron's investigational drug delivery system for treating central nervous system disorders, such as subarachnoid haemorrhage, spinal cord injury, traumatic brain injury and stroke.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.